Amy Thomas, APRN
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$655
- AstraZeneca$596
- Lilly USA, LLC$531
- Johnson & Johnson$370
- Pfizer$358
- plus $3K from 35 others
What the payments were for
- Food & beverage$7,37899%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$235
- VRAYLAR$226
- Otezla$124
- MOUNJARO$122
- Austedo XR$119
- DEXCOM G7 GSS (161)$117
- QULIPTA$115
- Repatha$114
- INVEGA SUSTENNA$113
How this compares
$7,478 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $193,581 |
| EliquisApixaban | 90 | $88,896 |
| MounjaroTirzepatide | 65 | $78,653 |
| TrulicityDulaglutide | 40 | $58,260 |
| JardianceEmpagliflozin | 54 | $57,717 |
| FarxigaDapagliflozin Propanediol | 45 | $35,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $26,174 |
| XareltoRivaroxaban | 18 | $22,876 |
| JanuviaSitagliptin Phosphate | 22 | $22,529 |
| RybelsusSemaglutide | 11 | $17,825 |
| LinzessLinaclotide | 13 | $16,309 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $15,947 |
| TrintellixVortioxetine Hydrobromide | 13 | $15,237 |
| MyrbetriqMirabegron | 21 | $10,781 |
| NeuproRotigotine | 12 | $9,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $655 | $211,406145 claims |
| Lilly USA, LLCMounjaro, Trulicity | $531 | $136,913105 claims |
| PfizerEliquis | $358 | $88,89690 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $82 | $73,66470 claims |
| AstraZenecaFarxiga, Symbicort | $596 | $44,99272 claims |
| GSKTrelegy Ellipta | $272 | $26,17430 claims |
| Johnson & JohnsonXarelto | $370 | $22,87618 claims |
| MerckJanuvia | $28 | $22,52922 claims |
| AbbVieLinzess, Synthroid | $1,477 | $21,53662 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $81 | $15,23713 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $10,78121 claims |
| NovartisEntresto | $17 | $7,59011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Jillian OakleafTulsa$15K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Jaclyn DrassTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.